中枢神経系治療薬市場：疾患別、薬剤タイプ別、投与経路別、エンドユーザー別-2025-2030年の世界予測

中枢神経系治療薬市場は、2023年に1,338億3,000万米ドルと評価され、2024年には1,431億1,000万米ドルに達すると予測され、CAGR 7.24％で成長し、2030年には2,184億5,000万米ドルに達すると予測されます。

中枢神経系（CNS）治療薬市場には、アルツハイマー病、パーキンソン病、多発性硬化症、うつ病などの神経疾患や疾病を対象とする幅広い治療が含まれます。この市場を牽引しているのは、人口の高齢化、意識の高まり、ヘルスケアアクセスの拡大による神経疾患の有病率の増加です。中枢神経系治療薬の必要性は、これらの疾患がもたらす大きな社会的・経済的負担によって強調されており、革新的な治療選択肢と患者の転帰の改善が不可欠となっています。用途は医薬品、遺伝子・細胞療法、革新的な送達システムなど多岐にわたり、中枢神経系疾患の急性期と慢性期の両方に対応しています。主なエンドユーザーには、病院、診療所、研究機関が含まれます。市場成長は、ドラッグデリバリー技術の進歩、診断技術の向上、新規生物製剤の流入の影響を受けています。個別化医療の探求には機会が多く、標的療法を創出するためのゲノミクスに重点が置かれています。研究開発における共同努力、創薬への人工知能の活用、希少疾病用医薬品の指定などの規制上の優遇措置は、急成長する機会を活用するための潜在的なルートです。しかし、市場は多額の研究開発コスト、厳しい規制状況、インフラのハードルによる新興国地域への浸透の課題などの制約に直面しています。また、予測モデル・システムの不足や血液脳関門を通過することの難しさは、依然として根強い課題です。これらに対処するには、バイオマーカー、臨床試験デザインの改善、脳の足場技術の革新が変革をもたらす可能性があります。中枢神経系治療薬市場の性質はダイナミックで、ハイリスク・ハイリターンであるため、継続的なイノベーションと機敏性が求められます。企業には、共同研究への投資、戦略的パートナーシップの育成、技術的進歩の活用を図りつつ、規制や事業運営上の課題に対処することが勧められます。包括的な患者ケアソリューションに焦点を当て、デジタルヘルス技術を活用することで、この進化する情勢において持続可能な競争力を生み出すことができると思われます。

市場力学：急速に進化する中枢神経系治療薬市場の主要市場インサイトを公開

中枢神経系治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者人口の増加と神経変性疾患の流行
  • 神経疾患の研究に対する政府の取り組みと資金援助
• 市場抑制要因
  • 中枢神経系疾患に関連する製品回収事例の増加
• 市場機会
  • 神経変性疾患に対する遺伝子編集技術や幹細胞研究への投資
  • 革新的な薬剤製剤のためのナノ材料利用の可能性
• 市場の課題
  • 中枢神経系疾患の複雑さと血液脳関門通過の困難さ

ポーターの5つの力：中枢神経系治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：中枢神経系治療薬市場における外部からの影響の把握

外部マクロ環境要因は、中枢神経系治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析中枢神経系治療薬市場における競合情勢の把握

中枢神経系治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス中枢神経系治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、中枢神経系治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨中枢神経系治療薬市場における成功への道筋を描く

中枢神経系治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口の増加と神経変性疾患の蔓延
    • 神経疾患に関する調査に対する政府の取り組みと資金提供の実施
  • 抑制要因
    • 中枢神経系薬に関連する製品回収件数が増加
  • 機会
    • 神経変性疾患に対する遺伝子編集技術と幹細胞調査への投資
    • 革新的な医薬品製剤のためのナノ材料の潜在的利用
  • 課題
    • 中枢神経系疾患の複雑さと血液脳関門通過の難しさ
• 市場セグメンテーション分析
  • 疾患：てんかん疾患の有病率の増加と満たされていない医療ニーズの増大
  • 薬剤の種類：特定の強力な治療のための革新的な生物学的製剤
  • 投与経路：長時間作用型の製剤のため、注射剤が好まれます。
  • エンドユーザー：病院では即時介入のための中枢神経系治療薬に対する大きな需要がある
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 中枢神経系治療薬市場障害別

• てんかん疾患
  • てんかん
  • 発作性疾患
• 神経変性疾患
  • アルツハイマー病
  • 筋萎縮性側索硬化症
  • 多発性硬化症
  • パーキンソン病
• 疼痛管理
  • 急性疼痛
  • 慢性疼痛
  • 神経障害性疼痛
• 精神疾患
  • 不安障害
  • 双極性障害
  • うつ
  • 統合失調症

第7章 中枢神経系治療薬市場薬の種類別

• 生物学的製剤
  • 遺伝子治療
  • モノクローナル抗体
  • ペプチド
  • 幹細胞療法
• 小分子

第8章 中枢神経系治療薬市場：投与経路別

• 注射可能
  • 筋肉内
  • 静脈内
  • 皮下
• オーラル
• 経皮

第9章 中枢神経系治療薬市場：エンドユーザー別

• 病院
• 調査機関
• 専門クリニック

第10章 南北アメリカの中枢神経系治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の中枢神経系治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの中枢神経系治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アムニール・ファーマシューティカルズ、パーキンソン病治療を強化するCREXONTのFDA承認を取得
  • アセンニューロン、神経変性疾患治療薬ASN51の開発に向け1億米ドルを確保
  • イーライリリーのキサンラがアルツハイマー病の早期治療としてFDAの承認を取得
  • ロシュとアシディアン・セラピューティクスが協力し、神経疾患に対する革新的なRNA治療法を開発
  • ボイジャー・セラピューティクス、アルツハイマー病治療薬VY-TAU01の第1a相試験を開始
  • スーパーナス・ファーマシューティカルズ、SPN-830に関するFDAの完全回答書簡を受領
  • サノフィ・インドは、患者の転帰を改善するために、Ciplaと提携してCNS治療薬の流通とプロモーションを強化します。
  • エングレイル・セラピューティクス、非依存性中枢神経系治療の発展と戦略的パートナーシップの拡大のため1億5,700万米ドルのシリーズB資金調達を確保
  • ミロバラン・セラピューティクス、中枢神経系治療の進歩に向けてシリーズA資金調達で2,400万米ドルを確保
  • アッヴィ、EUで進行性パーキンソン病に対する画期的な24時間皮下注入療法「プロデュオドパ」を発売
  • 4D Molecular TherapeuticsとArbor Biotechnologiesが提携し、中枢神経系疾患に対する革新的な遺伝子治療を推進
  • MapLight Therapeutics、CNS治療の進歩に向けて2億2,500万米ドルのシリーズC資金調達を確保
  • ファーマノビア、サノフィから11のCNSブランドを買収し神経学ポートフォリオを拡大
  • ノバルティス、siRNAに特化したDTx Pharmaを5億米ドルで買収し、神経科学パイプラインを強化
  • ニューロクライン・バイオサイエンシズ、ボイジャー・セラピューティクスと1億7,500万米ドルの遺伝子治療契約で提携
• 戦略分析と提言
  • F.ホフマン・ラ・ロシュAG
  • ブリストル・マイヤーズスクイブ社
  • ルパンリミテッド
  • アッヴィ株式会社

企業一覧

• AbbVie Inc.
• AC Immune SA
• Acadia Pharmaceuticals Inc.
• Acorda Therapeutics, Inc.
• Alkermes PLC
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• C.H. Boehringer Sohn AG & Co. KG
• Cassava Sciences, Inc.
• Cipla Limited
• CNS Pharmaceuticals, Inc.
• Denali Therapeutics Inc.
• Eisai Co. Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• H. Lundbeck A/S
• Intra-Cellular Therapies, Inc.
• Ipsen S.A.
• Johnson & Johnson Services, Inc.
• Lupin Limited
• MapLight Therapeutics, Inc.
• Merck KGaA
• Minerva Neurosciences, Inc.
• Neuraxpharm
• Novartis AG
• Novo Nordisk A/S
• Otsuka Holdings Co Ltd
• Pfizer Inc.
• Polpharma Biologics S.A.
• Rapport Therapeutics, Inc.
• Sage Therapeutics, Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Limited
• Supernus Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• TauRx Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

LIST OF FIGURES

• FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SEIZURE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 80. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 81. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 82. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 84. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 85. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 87. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 89. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 133. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 134. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 135. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 136. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 137. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 139. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 141. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 142. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 143. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 144. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 145. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 146. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 147. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 149. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 151. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 181. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 191. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 201. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 221. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 231. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 241. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 261. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 262. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 271. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 272. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 282. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD

The Central Nervous System Therapeutics Market was valued at USD 133.83 billion in 2023, expected to reach USD 143.11 billion in 2024, and is projected to grow at a CAGR of 7.24%, to USD 218.45 billion by 2030.

The Central Nervous System (CNS) Therapeutics market encompasses a broad range of treatments targeting neurological disorders and diseases, including Alzheimer's, Parkinson's, multiple sclerosis, and depression. This market is driven by the increasing prevalence of neurological disorders due to aging populations, rising awareness, and expanding healthcare access. The necessity for CNS therapeutics is underscored by the significant social and economic burden posed by these diseases, making innovative treatment options and improved patient outcomes critical. Applications span across pharmaceuticals, gene and cell therapies, and innovative delivery systems, catering to both acute and chronic aspects of CNS disorders. Key end-users include hospitals, clinics, and research institutions. Market growth is influenced by advancements in drug delivery technologies, improved diagnostic techniques, and an influx of novel biologics. Opportunities abound in the exploration of personalized medicine, with a focus on genomics to create targeted therapies. Collaborative efforts in R&D, artificial intelligence utilization for drug discovery, and regulatory incentives like orphan drug designation are potential routes to capitalize on burgeoning opportunities. However, the market faces limitations such as significant R&D costs, stringent regulatory landscapes, and challenges in penetrating developing regions due to infrastructure hurdles. The scarcity of predictive model systems and difficulty in crossing the blood-brain barrier remain persistent challenges. To address these, innovation in biomarkers, improved clinical trial designs, and brain scaffold technologies could be transformative. The nature of the CNS therapeutics market is dynamic, with a high-risk, high-reward profile demanding continuous innovation and agility. Companies are advised to invest in collaborative research, foster strategic partnerships, and leverage technological advancements while navigating the regulatory and operational challenges. Focusing on comprehensive patient care solutions and leveraging digital health technologies could create a sustainable competitive edge in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing elderly population and the prevalence of neurodegenerative disorders
  • Implementation of government initiatives & funding for research on neurological disorders
• Market Restraints
  • Rising cases of product recall associated with the CNS drugs
• Market Opportunities
  • Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
  • Potential utilization of nanomaterials for innovative drug formulation
• Market Challenges
  • Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier

Porter's Five Forces: A Strategic Tool for Navigating the Central Nervous System Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Nervous System Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Nervous System Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Nervous System Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Nervous System Therapeutics Market

A detailed market share analysis in the Central Nervous System Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Nervous System Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Nervous System Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Nervous System Therapeutics Market

A strategic analysis of the Central Nervous System Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Alkermes PLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc., Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Ipsen S.A., Johnson & Johnson Services, Inc., Lupin Limited, MapLight Therapeutics, Inc., Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., Polpharma Biologics S.A., Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disorders, market is studied across Epileptic Disorders, Neurodegenerative Diseases, Pain Management, and Psychiatric Disorders. The Epileptic Disorders is further studied across Epilepsy and Seizure Disorders. The Neurodegenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Pain Management is further studied across Acute Pain, Chronic Pain, and Neuropathic Pain. The Psychiatric Disorders is further studied across Anxiety Disorders, Bipolar Disorder, Depression, and Schizophrenia.
• Based on Drug Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Gene Therapies, Monoclonal Antibodies, Peptides, and Stem Cell Therapies.
• Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.
• Based on End-Users, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing elderly population and the prevalence of neurodegenerative disorders
    • 5.1.1.2. Implementation of government initiatives & funding for research on neurological disorders
  • 5.1.2. Restraints
    • 5.1.2.1. Rising cases of product recall associated with the CNS drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
    • 5.1.3.2. Potential utilization of nanomaterials for innovative drug formulation
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disorders: Increasing epileptic disorder prevalence and significant unmet medical needs
  • 5.2.2. Drug Type: Innovative biologics for particular and potent treatments
  • 5.2.3. Route of Administration: High preference for injectable routes owing to their long-acting formulations
  • 5.2.4. End-Users: Significant demand for CNS therapeutics in hospitals for immediate interventions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Central Nervous System Therapeutics Market, by Disorders

• 6.1. Introduction
• 6.2. Epileptic Disorders
  • 6.2.1. Epilepsy
  • 6.2.2. Seizure Disorders
• 6.3. Neurodegenerative Diseases
  • 6.3.1. Alzheimer's Disease
  • 6.3.2. Amyotrophic Lateral Sclerosis
  • 6.3.3. Multiple Sclerosis
  • 6.3.4. Parkinson's Disease
• 6.4. Pain Management
  • 6.4.1. Acute Pain
  • 6.4.2. Chronic Pain
  • 6.4.3. Neuropathic Pain
• 6.5. Psychiatric Disorders
  • 6.5.1. Anxiety Disorders
  • 6.5.2. Bipolar Disorder
  • 6.5.3. Depression
  • 6.5.4. Schizophrenia

7. Central Nervous System Therapeutics Market, by Drug Type

• 7.1. Introduction
• 7.2. Biologics
  • 7.2.1. Gene Therapies
  • 7.2.2. Monoclonal Antibodies
  • 7.2.3. Peptides
  • 7.2.4. Stem Cell Therapies
• 7.3. Small Molecules

8. Central Nervous System Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Intravenous
  • 8.2.3. Subcutaneous
• 8.3. Oral
• 8.4. Transdermal

9. Central Nervous System Therapeutics Market, by End-Users

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Research Institutes
• 9.4. Specialty Clinics

10. Americas Central Nervous System Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Central Nervous System Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Amneal Pharmaceuticals receives FDA approval for CREXONT to enhance Parkinson's therapy
  • 13.3.2. Asceneuron secures USD 100M to advance ASN51 for neurodegenerative diseases
  • 13.3.3. Eli Lilly's Kisunla receives FDA approval for early Alzheimer's treatment
  • 13.3.4. Roche and Ascidian Therapeutics join forces to develop innovative RNA therapies for neurological diseases
  • 13.3.5. Voyager Therapeutics initiates Phase 1a trial of VY-TAU01 for Alzheimer's
  • 13.3.6. Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830
  • 13.3.7. Sanofi India partners with Cipla to enhance distribution and promotion of CNS therapeutics to improve patient outcomes
  • 13.3.8. Engrail Therapeutics secures USD 157M Series B funding to advance non-addictive CNS therapies and expand strategic partnerships
  • 13.3.9. Myrobalan Therapeutics secures USD 24 million in Series A funding to advance CNS treatments
  • 13.3.10. AbbVie launches Produodopa, a groundbreaking 24-hour subcutaneous infusion therapy for advanced Parkinson's in the EU
  • 13.3.11. 4D Molecular Therapeutics and Arbor Biotechnologies partner to advance innovative genetic therapies for CNS disorders
  • 13.3.12. MapLight Therapeutics secures USD 225 million Series C funding to advance CNS therapies
  • 13.3.13. Pharmanovia expands neurology portfolio by acquiring 11 CNS brands from Sanofi
  • 13.3.14. Novartis strengthens neuroscience pipeline with USD 500M acquisition of siRNA-focused DTx Pharma
  • 13.3.15. Neurocrine Biosciences collaborates with Voyager Therapeutics on USD 175M gene therapy deal
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. F. Hoffmann-La Roche AG
  • 13.4.2. Bristol-Myers Squibb Company
  • 13.4.3. Lupin Limited
  • 13.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. AC Immune SA
• 3. Acadia Pharmaceuticals Inc.
• 4. Acorda Therapeutics, Inc.
• 5. Alkermes PLC
• 6. Amgen Inc.
• 7. AstraZeneca PLC
• 8. Bayer AG
• 9. Biogen Inc.
• 10. Bristol-Myers Squibb Company
• 11. C.H. Boehringer Sohn AG & Co. KG
• 12. Cassava Sciences, Inc.
• 13. Cipla Limited
• 14. CNS Pharmaceuticals, Inc.
• 15. Denali Therapeutics Inc.
• 16. Eisai Co. Ltd.
• 17. Eli Lilly and Company
• 18. F. Hoffmann-La Roche AG
• 19. GlaxoSmithKline PLC
• 20. H. Lundbeck A/S
• 21. Intra-Cellular Therapies, Inc.
• 22. Ipsen S.A.
• 23. Johnson & Johnson Services, Inc.
• 24. Lupin Limited
• 25. MapLight Therapeutics, Inc.
• 26. Merck KGaA
• 27. Minerva Neurosciences, Inc.
• 28. Neuraxpharm
• 29. Novartis AG
• 30. Novo Nordisk A/S
• 31. Otsuka Holdings Co Ltd
• 32. Pfizer Inc.
• 33. Polpharma Biologics S.A.
• 34. Rapport Therapeutics, Inc.
• 35. Sage Therapeutics, Inc.
• 36. Sanofi S.A.
• 37. Sun Pharmaceutical Industries Limited
• 38. Supernus Pharmaceuticals, Inc.
• 39. Takeda Pharmaceutical Company Limited
• 40. TauRx Pharmaceuticals Ltd
• 41. Teva Pharmaceutical Industries Ltd.
• 42. UCB S.A.